 MONMOUTH JUNCTION, N.J., Oct. 12, 2021 PRNewswire -- CytoSorbents Corporation NASDAQ: CTSO, a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces preliminary third quarter financial results and revised second half and full year 2021 product revenue guidance, primarily reflecting pandemic-driven adverse market conditions in Germany. 